Carmoterol Explained

Carmoterol (INN;[1] development codes TA-2005 and CHF-4226) is a non-catechol[2] experimental ultra-long-acting β adrenoreceptor agonist (ultra-LABA)[3] that was in clinical trials before 2010 when it has been withdrawn from further development based on evidence that the compound does not possess a competitive profile.[4]

Preliminary studies indicated duration of its effect exceeding 24 hours after inhalation of 3 μg. The pharmacologic profile of this medication included the fact its potency in isolated guinea pig trachea is greater than that of formoterol and salmeterol. It is over 100 times more selective for bronchial muscle than myocardial tissue.[5]

Notes and References

  1. International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53. WHO Drug Information. 2005. 19. 1. 74. 25 March 2016.
  2. Book: Mario C, Monica K . Clinical Asthma. 2008. Mosby / Elsevier Health Sciences. Philadelphia, PA . 978-0-323-04289-5. 27. Bronchodilators: Beta2-Agonists and Anticholingercs.
  3. Cazzola M, Calzetta L, Matera MG . β(2) -adrenoceptor agonists: current and future direction . British Journal of Pharmacology . 163 . 1 . 4–17 . May 2011 . 21232045 . 3085864 . 10.1111/j.1476-5381.2011.01216.x .
  4. Web site: Chiesi: Annual Report 2010 . Chiesi Farmaceutici S.p.A.. 27 March 2016. 20.
  5. Web site: Donohue JF . New Options in COPD Therapy . Medscape . 2006 . 27 March 2016.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Carmoterol".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.